Physician profile
Jonathan D Wade
NPI 1528297538
$473.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.39 · 2021: $30.80 · 2022: $130 · 2023: $142 · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $146.75 | 2023-2024 | Qelbree, Qelbree |
| Novo Nordisk INC | $90.71 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $45.25 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $30.26 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.92 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $24.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.44 | 2023 | Jardiance |
| Amgen INC. | $18.75 | 2022 | |
| Abbott Laboratories | $17.82 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.11 | 2022 | |
| Bausch Health US, LLC | $13.39 | 2023 | Aplenzin |
| Abbvie INC. | $13.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.